Grupo Espanol De Tumores Neuroendocrinos

This study tested whether adding the oral drug axitinib to the standard treatment sandostatin LAR could slow cancer growth in people with advanced neuroendocrine tumors that started outside the pancreas. 256 adults with tumors that had recently grown were randomly assigned to get…

This study tested the drug cabozantinib in 41 adults with advanced thyroid cancer that stopped responding to radioactive iodine. The main goal was to find genetic markers in the blood that might predict how well the drug works. Researchers also tracked tumor shrinkage and how lon…

This study looked back at the medical records of 19 Spanish patients with rare cancers caused by NTRK gene fusions. All patients had received the targeted drug larotrectinib through a compassionate use program before it was widely available. The goal was to learn how well the dru…